KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.50

Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice.

Iris Hochstenbach, Julie J M Hamm, Eva Rademaker, Arend G J Aalbers, Djamila Boerma, Wilhelmina M U van Grevenstein, Patrick H J Hemmer, Ignace H J T De Hingh, Niels F M Kok, Jurriaan B Tuynman, Eva V E Madsen, Johannes H W de Wilt, Esther C J Consten, Henderik L van Westreenen, Pieter J Tanis, COLOPEC Collaborators Group, Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative

Colorectal Dis 28(9) e70614

PMID42755020
PMCIDPMC13586421
DOI10.1111/codi.70614
发表日期2026-09-18
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

AIM: The randomized COLOPEC trial demonstrated no benefit of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in preventing peritoneal metastases in locally advanced colon cancer. Because all patients underwent a diagnostic laparoscopy at 18 months, the study lacked a true control arm, leaving the effect of early detection and treatment compared with standard care uncertain. This study aimed to compare long-term oncological outcomes between patients treated in the COLOPEC trial and patients treated in routine care. METHOD: Patients who underwent curative resection for c/pT4 or perforated colon cancer in the COLOPEC trial were compared with a retrospective control cohort that included all colon cancer resections performed in 2014-2015, in 50 Dutch hospitals. All 202 trial patients were matched 1:1 to 202 control patients using propensity score matching. RESULTS: Following treatment in both arms of the COLOPEC trial, compared to the matched control cohort, 5-year overall survival was 70.2% versus 72.8% (p = 0.77). Five-year disease-free survival was 62.1% versus 65.2% (p = 0.31) and five-year cumulative incidence of peritoneal metastases was 24.4% Versus 9.5% (p < 0.001). Cytoreductive surgery with HIPEC for peritoneal recurrence was performed in 28 (13.9%) versus 7 patients (3.5%; p < 0.001). CONCLUSION: Despite increased detection and more frequent treatment of peritoneal metastases in the COLOPEC trial, 5-year overall and disease-free survival were comparable to routine practice.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。